先進藥物傳輸系統（DDS）：技術以及全球市場 是由出版商BCC Research在2011年10月所出版的。
這份英文市場調查報告書價格從美金4850起跳。
本報告，調查全球Drug Delivery（藥物傳輸）市場的現狀與將來動向，以最終使用者別、應用別彙整市場概要、各種劑型的使用與將來的方向性、市場所環抱的課題等，由下列摘要形式闡述。
第1章 簡介
第2章 報告摘要
第3章 概要
- 定義
- 劑型的需求
- 服用方式的藥物傳輸分類
- 技術基礎的藥物傳輸分類
- 應用別分類
第4章 法律規範面
第5章 業界結構
- 製造商／供應商
- 長時間釋放劑型
- 前驅藥
- 經皮藥物傳輸系統
- 肺部藥物傳輸系統
- 口腔藥物傳輸系統
- 眼球藥物傳輸系統
- 直腸藥物傳輸系統
- 經陰道藥物傳輸系統
- 標的藥物傳輸系統
- 高分子藥物傳輸系統
- 業界領導者的市佔率
第6章 新開發
第7章 市場分析
- 市場收益
- 長時間釋放
- 注射
- 局部
- 前驅藥
- 經皮藥物傳輸
- 植入以及IUD
- 肺部藥物傳輸／吸入
- 口腔藥物傳輸系統
- 眼球藥物傳輸系統
- 經陰道藥物傳輸系統
- 標的藥物傳輸系統
- 高分子藥物傳輸系統
- PEG產品
- 地區別市佔率
第8章 最終使用者別市場
- 心血管疾病
- 癌症
- 腸胃系統
- 泌尿系統
- 糖尿病
- 中樞神經系統
- 呼吸器官
- 發炎疾病・過敏
- 眼科
- 病毒・細菌性疾病
- 荷爾蒙補充療法與婦產科
- 其他
- 技術
- 應用別市佔率
第9章 專利分析
第10章 現況、策略、展望
- 市場現況
- 影響藥物傳輸市場的因子
- 企業策略
- 需求與動向
第11章 企業檔案資料
第12章 附錄
圖表
Abstract
REPORT HIGHLIGHTS
THIS REPORT CONTAINS:
- An overview of the major types of drug delivery systems used in the
healthcare industry
- Analyses of global market trends, with data from 2009 and 2010, estimates
for 2011, and projections of compound annual growth rates (CAGRs) through 2016
- Coverage of each technology and the manufacturers' new products, sales
estimates, market projections, and market share information
- Evaluations of patents for drug delivery technologies by year, country,
and assignee
- Examination of Food and Drug Administration (FDA) approvals for the past
five years
- Comprehensive company profiles.
SUMMARY FIGURE
GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS
BY REGION, 2009-2016 ($ MILLIONS)
Source: BCC Research
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current
and future characteristics of the global market for drug delivery, including
the market as seen by the end users of the different applications of drug
delivery. The key objective is to present a comprehensive analysis of the
current drug delivery market and its future direction with the utilization of
the various delivery methods to prevent globally widespread diseases.
This report explores present and future strategies within the drug delivery
market, including the market size, market leaders, market overview, and
various other factors affecting the market of drug delivery, with the
inclusion of the market by end users. The current state of the market, the
setbacks, the innovations, and the future needs of the market are also
discussed in this report.
A detailed analysis of the drug delivery market with the industry structure
has been conducted. This includes all the different categories/applications
of drug delivery, broken down by market share belonging to leading
manufacturers and/or suppliers. Revenues for each of the categories of drug
delivery are broken down by region. Sales figures are estimated for the
5-year period from 2011 through 2016.
Applications of drug delivery, including new and advanced drug delivery
methods, are also discussed separately in the report, by region. The
strategies and the prospects of the current market are also discussed.
Companies that manufacture/sell new and innovative drug delivery technologies
are also profiled. The revenues have been broken down by the type of
technology and by different regions.
REASONS FOR DOING THIS STUDY
This study was conducted to provide detailed information regarding drug
delivery technologies due to an increasing need for new and innovative
technologies, especially those that supplement the production and manufacture
of new drugs. This industry is experiencing growth as consumers are now
adapting to new drugs and as such the use of new drug delivery technologies
has increased. The study looks at almost all types of drug delivery
technologies and applications. The study conducts the research and
development of almost all new technologies and applications. The changes in
market behavior justify focusing on this segment. Additionally, this study
discusses the usage of these technologies by the end users. Acquisitions,
mergers, and alliances by companies and global organizations are also
discussed in this report.
SCOPE OF THE STUDY
The scope of this study encompasses the drug delivery markets by various
types. BCC analyzes each market by its category with its applications in
different regions of the world. It also analyzes the market leaders, the
regulatory environment, technology involved, market projections, and market
share. Technological issues include the latest trends and developments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this
study. BCC conducted a comprehensive literature search, which included
technical newsletters and journals, and many other sources. Data were
collected through interviews and correspondence with various trade experts.
Projections were based on estimates such as the current number of end users,
potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this
study. Included were manufacturers, end users of drug delivery systems, which
included pharmaceutical and biotechnical industries, research institutes, etc.
Data were gathered from various industry sources. BCC spoke with officials
within the industry, consulted newsletters, company literature, product
literature, and a host of technical articles, journals, indexes, and
abstracts. Exhaustive investigations of databases by key terminology were
completed. In addition, data were compiled from current financial, trade, and
government sources.
ABOUT THE AUTHOR
The study has been carried out by a team of professionals in the biotechnology
industry. The project manager for this project is Shalini S. Dewan, who holds
a master's degree in Pharmaceutical Chemistry and has more than 14 years of
industry experience. Among the research topics she has covered are studies on
compounds of potential pharmaceutical interest from ibuprofen to 2-naphthyl
acetic acid. Dewan was awarded a Gold Medal by the Prime Minister of India
for her work and has worked with top companies in India and in the U.S.
The lead consultant for this project was Dr. Kapil A. Setia, who holds a
doctoral degree in life sciences. She has a number of research publications
to her credit, including her thesis on Studies on Phenotypic Variation, Clonal
Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.).
Table of Contents
Advanced Drug Delivery Systems: Technologies and Global Markets
Chapter - 1: INTRODUCTION - Complimentary
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- INTENDED AUDIENCE
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- BCC ONLINE SERVICES
- ABOUT THE AUTHOR
- RELATED BCC RESEARCH REPORTS
- DISCLAIMER
Chapter - 2: EXECUTIVE SUMMARY
- Table 0: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Figure 0: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY REGION,
2009-2016
Chapter - 3: OVERVIEW
- DEFINITIONS
- NEED FOR THE DOSAGE FORMS
- CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION
- CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY
- REASONS AND EVOLUTION OF DRUG DELIVERY TECHNOLOGIES
- CLASSIFICATION BY APPLICATION
- Table 19: APPLICATIONS OF SUSTAINED RELEASE DOSAGE FORMS
- Table 20: APPLICATIONS OF PRODRUGS
- Table 21: APPLICATIONS OF TRANSDERMAL DRUG DELIVERY
- Table 22: APPLICATIONS OF IMPLANTS AND IUDS
- Table 23: APPLICATIONS FOR PULMONARY DRUG DELIVERY
- Table 24: APPLICATIONS OF BUCCAL DRUG DELIVERY
- Table 25: APPLICATIONS OF RECTAL DRUG DELIVERY
- Table 26: APPLICATIONS OF OCULAR DRUG DELIVERY
- Table 27: APPLICATIONS OF VAGINAL DRUG DELIVERY
- Table 28: APPLICATIONS OF LIPOSOMES
- Table 29: APPLICATIONS OF NANOPARTICLES
- Table 30: APPLICATIONS OF NANOPARTICLES
- Table 31: APPLICATIONS OF POLYMERS
- Table 32: APPLICATIONS OF PEGYLATION
Chapter - 4: REGULATORY ASPECTS
- Table 33: NEW APPROVALS OF VARIOUS ADVANCED DRUG DELIVERY SYSTEMS, 2008 TO
JUNE 2011
- Table 34: SAFETY ALERTS, JULY 2007 TO JUNE 2011
Chapter - 5: INDUSTRY STRUCTURE
- MANUFACTURERS/ SUPPLIERS OF DRUG DELIVERY SYSTEMS
- MARKET SHARES OF INDUSTRY LEADERS OF DRUG DELIVERY SYSTEMS
Chapter - 6: NEW DEVELOPMENTS
- Table 67: NEW DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS
- Table 68: NEW DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- Table 69: NEW DEVELOPMENTS IN TOPICAL ORAL DOSAGE FORMS
- Table 70: NEW DEVELOPMENTS IN IMPLANTS AND IUDS
- Table 71: NEW DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 72: NEW DEVELOPMENTS IN LIPOSOMAL DRUG DELIVERY
- Table 73: NEW DEVELOPMENTS IN PEGYLATED DRUG DELIVERY
- Table 74: NEW DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY
- Table 75: NEW DEVELOPMENTS IN BUCCAL DRUG DELIVERY
- Table 76: NEW DEVELOPMENTS IN VAGINAL DRUG DELIVERY
- Table 77: NEW DEVELOPMENTS IN RECTAL DRUG DELIVERY
- Table 78: NEW DEVELOPMENTS IN INHALATION DRUG DELIVERY
- Table 79: NEW DEVELOPMENTS IN PRODRUGS
- Table 80: NEW DEVELOPMENTS IN MONOCLONAL ANTIBODIES
Chapter - 7: MARKET ANALYSIS
- MARKET REVENUE
- Table 81: GLOBAL MARKET FOR ADVANCED DRUG DELIVERY SYSTEM, THROUGH 2016
- Figure 17: GLOBAL MARKET FOR ADVANCED DRUG DELIVERY SYSTEM, 2009-2016
Chapter - 8: MARKET BY END USERS
- CARDIOVASCULAR DISEASES
- ONCOLOGY
- GASTROINTESTINAL SYSTEMS
- UROLOGY
- DIABETES
- CENTRAL NERVOUS SYSTEM
- RESPIRATORY DRUG DELIVERY SYSTEMS
- INFLAMMATORY DISEASES AND ALLERGIES
- OPHTHALMOLOGY
- VIRAL AND BACTERIAL DISEASES
- HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY
- OTHERS
- TECHNOLOGIES
- MARKET SHARE OF APPLICATIONS
- Table 126: SHARES OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2010
- Figure 62: SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2010
Chapter - 9: PATENT ANALYSIS
- PATENTS BY YEAR
- PATENTS BY TYPE
- PATENTS BY COMPANY
- PATENTS BY COUNTRY
- PATENTS BY ASSIGNEE
- Table 131: PATENTS BY ASSIGNEE FOR DRUG DELIVERY SYSTEMS, 2007 - 2011
- Figure 66: PATENTS BY ASSIGNEE FOR DRUG DELIVERY SYSTEMS, 2007 - 2011
Chapter - 10: CURRENT SITUATION, STRATEGIES, AND PROSPECTS
- MARKET STATUS
- FACTORS AFFECTING THE DRUG DELIVERY MARKET
- COMPANY STRATEGIES
- DEMANDS AND TRENDS
Chapter - 11: COMPANY PROFILES
- ABBOTT LABORATORIES
- AKELA PHARMA INC.
- AKORN INC.
- ALCON INC.
- ALEXION PHARMACEUTICALS
- ALKERMES, INC.
- ALLERGAN
- ALPHARX
- AMGEN
- A.P. PHARMA
- ASTELLAS PHARMA INC.
- ASTRAZENECA PLC
- ATON PHARMA
- BAXTER
- BAYER HEALTHCARE PHARMACEUTICALS
- BIOGEN IDEC
- BIOSANTE PHARMACEUTICALS INC.
- BOEHRINGER INGELHEIM
- BRISTOL MYERS SQUIBB
- CELGENE CORPORATION
- CEPHALON INC.
- COLUMBIA LABORATORIES INC.
- EISAI CO.
- ELAN DRUG TECHNOLOGIES
- ENZON PHARMACEUTICALS
- EURAND N.V.
- GENENTECH
- GENEREX BIOTECHNOLOGY CORPORATION
- GENZYME
- GILEAD SCIENCES, INC.
- GLAXOSMITHKLINE PLC
- IMCLONE SYSTEMS
- JANSSEN BIOTECH INC.
- JOHNSON & JOHNSON
- KV PHARMACEUTICAL CO.
- LAVIPHARM CORPORATION
- 3M COMPANY
- MERCK & CO.
- MYLAN LABORATORIES INC.
- NEKTAR THERAPEUTICS
- NEUROGESX INC.
- NOVEN PHARMACEUTICALS, INC.
- NOVARTIS AG
- NOVAVAX, INC.
- NYCOMED US INC.
- OSI PHARMACEUTICALS INC.
- PAR PHARMACEUTICAL COMPANIES, INC.
- PDL BIOPHARMA INC.
- PFIZER INC.
- QLT INC.
- ROCHE HOLDING AG
- SANOFI SA
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- VALEANT PHARMACEUTICALS INTERNATIONAL
- WATSON PHARMACEUTICALS, INC.
Chapter - 12: APPENDIX I - ABBREVIATIONS/DEFINITIONS
List of Tables
- Summary Table: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Table 1: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
- Table 2: ADVANTAGES AND DISADVANTAGES OF PARENTERAL DRUG DELIVERY
- Table 3: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
- Table 4: ADVANTAGES AND DISADVANTAGES OF METERED DOSE INHALERS
- Table 5: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
- Table 6: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY
- Table 7: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
- Table 8: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
- Table 9: ADVANTAGES AND DISADVANTAGES OF VAGINAL DRUG DELIVERY
- Table 10: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY
- Table 11: ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY
- Table 12: ADVANTAGES AND DISADVANTAGES OF PRODRUGS
- Table 13: ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS
- Table 14: ADVANTAGES AND DISADVANTAGES OF LIPOSOMES
- Table 15: ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES
- Table 16: ADVANTAGES AND DISADVANTAGES OF POLYMERS
- Table 17: ADVANTAGES AND DISADVANTAGES OF PEGYLATION
- Table 18: EVOLUTION OF DRUG DELIVERY TECHNOLOGIES
- Table 19: APPLICATIONS OF SUSTAINED RELEASE DOSAGE FORMS
- Table 20: APPLICATIONS OF PRODRUGS
- Table 21: APPLICATIONS OF TRANSDERMAL DRUG DELIVERY
- Table 22: APPLICATIONS OF IMPLANTS AND IUDS
- Table 23: APPLICATIONS FOR PULMONARY DRUG DELIVERY
- Table 24: APPLICATIONS OF BUCCAL DRUG DELIVERY
- Table 25: APPLICATIONS OF RECTAL DRUG DELIVERY
- Table 26: APPLICATIONS OF OCULAR DRUG DELIVERY
- Table 27: APPLICATIONS OF VAGINAL DRUG DELIVERY
- Table 28: APPLICATIONS OF LIPOSOMES
- Table 29: APPLICATIONS OF NANOPARTICLES
- Table 30: APPLICATIONS OF NANOPARTICLES
- Table 31: APPLICATIONS OF POLYMERS
- Table 32: APPLICATIONS OF PEGYLATION
- Table 33: NEW APPROVALS OF VARIOUS ADVANCED DRUG DELIVERY SYSTEMS, 2008
TO JUNE 2011
- Table 34: SAFETY ALERTS, JULY 2007 TO JUNE 2011
- Table 35: LEADING MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE ORAL
DOSAGE FORMS
- Table 36: LEADING MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE
INJECTABLE DOSAGE FORMS
- Table 37: LEADING MANUFACTURERS/SUPPLIERS OF SUSTAINED RELEASE TOPICAL
DOSAGE FORMS
- Table 38: LEADING MANUFACTURERS/SUPPLIERS OF PRODRUGS
- Table 39: LEADING MANUFACTURERS/SUPPLIERS OF IMPLANTS AND IUDS
- Table 40: LEADING MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY
SYSTEMS
- Table 41: LEADING MANUFACTURERS/SUPPLIERS OF PULMONARY DRUG DELIVERY
SYSTEMS
- Table 42: LEADING MANUFACTURERS/SUPPLIERS OF BUCCAL DELIVERY SYSTEMS
- Table 43: LEADING MANUFACTURERS/SUPPLIERS OF RECTAL DELIVERY SYSTEMS
- Table 44: LEADING MANUFACTURERS/SUPPLIERS OF OCULAR DELIVERY SYSTEMS
- Table 45: LEADING MANUFACTURERS/SUPPLIERS OF VAGINAL DELIVERY SYSTEMS
- Table 46: LEADING MANUFACTURERS/SUPPLIERS OF LIPOSOMES
- Table 47: LEADING MANUFACTURERS/SUPPLIERS OF NANOPARTICLES
- Table 48: LEADING MANUFACTURERS / SUPPLIERS OF MONOCLONAL ANTIBODIES
- Table 49: LEADING MANUFACTURERS/SUPPLIERS OF POLYMERS
- Table 50: LEADING MANUFACTURERS/SUPPLIERS OF PEGYLATED PRODUCTS
- Table 51: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED
RELEASE ORAL DOSAGE FORMS, 2010
- Table 52: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED
RELEASE INJECTABLE DOSAGE FORMS, 2010
- Table 53: GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUSTAINED
RELEASE INJECTABLE DOSAGE FORMS, 2010
- Table 54: GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF PRODRUGS,
2010
- Table 55: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF IMPLANTS
AND IUDS, 2010
- Table 56: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PULMONARY
DRUG DELIVERY SYSTEMS, 2010
- Table 57: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL
DRUG DELIVERY SYSTEMS, 2010
- Table 58: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF BUCCAL DRUG
DELIVERY SYSTEMS, 2010
- Table 59: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECTAL DRUG
DELIVERY SYSTEMS, 2010
- Table 60: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG
DELIVERY SYSTEM, 2010
- Table 61: GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL
DRUG DELIVERY SYSTEM, 2010
- Table 62: GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF LIPOSOMES,
2010
- Table 63: GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF
NANOPARTICLES, 2010
- Table 64: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL
ANTIBODIES, 2010
- Table 65: GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF POLYMERS,
2010
- Table 66: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY,
2010
- Table 67: NEW DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS
- Table 68: NEW DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- Table 69: NEW DEVELOPMENTS IN TOPICAL ORAL DOSAGE FORMS
- Table 70: NEW DEVELOPMENTS IN IMPLANTS AND IUDS
- Table 71: NEW DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 72: NEW DEVELOPMENTS IN LIPOSOMAL DRUG DELIVERY
- Table 73: NEW DEVELOPMENTS IN PEGYLATED DRUG DELIVERY
- Table 74: NEW DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY
- Table 75: NEW DEVELOPMENTS IN BUCCAL DRUG DELIVERY
- Table 76: NEW DEVELOPMENTS IN VAGINAL DRUG DELIVERY
- Table 77: NEW DEVELOPMENTS IN RECTAL DRUG DELIVERY
- Table 78: NEW DEVELOPMENTS IN INHALATION DRUG DELIVERY
- Table 79: NEW DEVELOPMENTS IN PRODRUGS
- Table 80: NEW DEVELOPMENTS IN MONOCLONAL ANTIBODIES
- Table 81: GLOBAL MARKET FOR ADVANCED DRUG DELIVERY SYSTEM, THROUGH 2016
- Table 82: GLOBAL MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY
REGION, THROUGH 2016
- Table 83: GLOBAL MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS BY
REGION, THROUGH 2016
- Table 84: GLOBAL MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY
REGION, THROUGH 2016
- Table 85: GLOBAL MARKET FOR PRODRUGS BY REGION, THROUGH 2016
- Table 86: GLOBAL MARKET FOR TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Table 87: GLOBAL MARKET FOR IMPLANTS AND IUDS BY REGION, THROUGH 2016
- Table 88: GLOBAL MARKET FOR PULMONARY DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Table 89: GLOBAL MARKET FOR BUCCAL DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Table 90: GLOBAL MARKET FOR RECTAL DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Table 91: GLOBAL MARKET FOR OCULAR DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Table 92: GLOBAL MARKET FOR VAGINAL DRUG DELIVERY SYSTEMS BY REGION,
THROUGH 2016
- Table 93: GLOBAL MARKET FOR NANOPARTICLES BY REGION, THROUGH 2016
- Table 94: GLOBAL MARKET FOR LIPOSOMES BY REGION, THROUGH 2016
- Table 95: GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2016
- Table 96: GLOBAL MARKET FOR POLYMERS BY REGION, THROUGH 2016
- Table 97: GLOBAL MARKET FOR PEGYLATED PRODUCTS BY REGION, THROUGH 2016
- Table 98: GLOBAL DRUG DELIVERY MARKET SHARES BY REGION, 2010
- Table 99: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATION,
THROUGH 2016
- Table 100: GLOBAL REVENUE FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,
THROUGH 2016
- Table 101: GLOBAL MARKET SHARES OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS
BY REGION, 2010
- Table 102: GLOBAL REVENUE FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH
2016
- Table 103: GLOBAL MARKET SHARES OF ONCOLOGY DRUG DELIVERY SYSTEMS BY
REGION, 2010
- Table 104: GLOBAL REVENUES FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,
THROUGH 2016
- Table 105: GLOBAL MARKET SHARES OF GASTROINTESTINAL DRUG DELIVERY
SYSTEMS BY REGION, 2010
- Table 106: GLOBAL REVENUE OF UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2016
- Table 107: GLOBAL MARKET SHARES OF UROLOGY DRUG DELIVERY SYSTEMS BY
REGION, 2010
- Table 108: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH
2016
- Table 109: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS IN DIABETES BY
REGION, 2010
- Table 110: GLOBAL REVENUES FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS, THROUGH 2016
- Table 111: GLOBAL MARKET SHARES OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS BY REGION, 2010
- Table 112: GLOBAL REVENUE FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH
2016
- Table 113: GLOBAL MARKET SHARES OF RESPIRATORY DRUG DELIVERY SYSTEMS BY
REGION, 2010
- Table 114: GLOBAL REVENUES FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY
DISEASES AND ALLERGIES, THROUGH 2016
- Table 115: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR
INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2010
- Table 116: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,
THROUGH 2016
- Table 117: GLOBAL MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY
BY REGION, 2010
- Table 118: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES, THROUGH 2016
- Table 119: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES BY REGION, 2010
- Table 120: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2016
- Table 121: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2010
- Table 122: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR OTHER DISEASES,
THROUGH 2016
- Table 123: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR OTHER
DISEASES BY REGION, 2010
- Table 124: GLOBAL REVENUE FOR DRUG DELIVERY TECHNOLOGIES, THROUGH 2016
- Table 125: GLOBAL MARKET SHARES OF DRUG DELIVERY TECHNOLOGIES BY REGION,
2010
- Table 126: SHARES OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2010
- Table 127: SIGNIFICANT PATENTS BY YEAR, 2007 - 2011
- Table 128: PATENTS BY TYPE, 2007 - 2011
- Table 129: NUMBER OF U.S. PATENTS BY COMPANY FOR DRUG DELIVERY SYSTEMS,
2007 - 2011
- Table 130: TOTAL NUMBER OF U.S. PATENTS BY COUNTRY, 2007 - 2011
- Table 131: PATENTS BY ASSIGNEE FOR DRUG DELIVERY SYSTEMS, 2007 - 2011
- Table 132: BRANDS COMING OFF-PATENT, 2011 - 2012
- Table 133: PRODUCTS OF NEKTAR VIA PARTNERSHIPS
- Table 134: PRODUCTS OF ELAN DRUG TECHNOLOGIES IN PARTNERSHIP
List of Figures
- Summary Figure: GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY
REGION, 2009-2016
- Figure 1: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED
RELEASE ORAL DOSAGE FORMS, 2010
- Figure 2: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED
RELEASE INJECTABLE DOSAGE FORMS, 2010
- Figure 3: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED
RELEASE TOPICAL DOSAGE FORMS, 2010
- Figure 4: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS,
2010
- Figure 5: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF IMPLANTS
AND IUDS, 2010
- Figure 6: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PULMONARY
DRUG DELIVERY SYSTEMS, 2010
- Figure 7: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL
DRUG DELIVERY SYSTEMS, 2010
- Figure 8: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF BUCCAL DRUG
DELIVERY SYSTEMS, 2010
- Figure 9: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECTAL DRUG
DELIVERY SYSTEMS, 2010
- Figure 10: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR
DRUG DELIVERY SYSTEMS, 2010
- Figure 11: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF VAGINAL
DRUG DELIVERY SYSTEMS, 2010
- Figure 12: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES,
2010
- Figure 13: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF
NANOPARTICLES, 2010
- Figure 14: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL
ANTIBODIES, 2010
- Figure 15: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS,
2010
- Figure 16: GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY,
2010
- Figure 17: GLOBAL MARKET FOR ADVANCED DRUG DELIVERY SYSTEM, 2009-2016
- Figure 18: GLOBAL MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY
REGION, 2009-2016
- Figure 19: GLOBAL MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
BY REGION, 2009-2016
- Figure 20: GLOBAL MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY
REGION, THROUGH 2016
- Figure 21: GLOBAL MARKET FOR PRODRUGS BY REGION, 2009-2016
- Figure 22: GLOBAL MARKET FOR TRANSDERMAL DRUG DELIVERY SYSTEMS BY
REGION, 2009-2016
- Figure 23: GLOBAL MARKET FOR IMPLANTS AND IUDS BY REGION, 2009-2016
- Figure 24: GLOBAL MARKET FOR PULMONARY DRUG DELIVERY SYSTEMS BY REGION,
2009-2016
- Figure 25: GLOBAL MARKET FOR BUCCAL DRUG DELIVERY SYSTEMS BY REGION,
2009-2016
- Figure 26: GLOBAL MARKET FOR RECTAL DRUG DELIVERY SYSTEMS BY REGION,
2009-2016
- Figure 27: GLOBAL MARKET FOR OCULAR DRUG DELIVERY SYSTEMS BY REGION,
2009-2016
- Figure 28: GLOBAL MARKET FOR VAGINAL DRUG DELIVERY SYSTEMS BY REGION,
2009-2016
- Figure 29: GLOBAL MARKET FOR NANOPARTICLES BY REGION, 2009-2016
- Figure 30: GLOBAL MARKET FOR LIPOSOMES BY REGION, 2009-2016
- Figure 31: GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2009-2016
- Figure 32: GLOBAL MARKET FOR POLYMERS BY REGION, 2009-2016
- Figure 33: GLOBAL MARKET FOR PEGYLATED PRODUCTS BY REGION, 2009-2016
- Figure 34: GLOBAL DRUG DELIVERY MARKET SHARES BY REGION, 2010
- Figure 35: GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATION,
2009-2016
- Figure 36: GLOBAL REVENUE FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,
2009-2016
- Figure 37: GLOBAL MARKET SHARES OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS
BY REGION, 2010
- Figure 38: GLOBAL REVENUE FOR ONCOLOGY DRUG DELIVERY SYSTEMS, 2009-2016
- Figure 39: GLOBAL MARKET SHARES OF ONCOLOGY DRUG DELIVERY SYSTEMS BY
REGION, 2010
- Figure 40: GLOBAL REVENUES FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS,
2009-2016
- Figure 41: GLOBAL MARKET SHARES OF GASTROINTESTINAL DRUG DELIVERY
SYSTEMS BY REGION, 2010
- Figure 42: GLOBAL REVENUE OF UROLOGY DRUG DELIVERY SYSTEMS, 2009-2016
- Figure 43: GLOBAL MARKET SHARES OF UROLOGY DRUG DELIVERY SYSTEMS BY
REGION, 2010
- Figure 44: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN DIABETES,
2009-2016
- Figure 45: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS IN DIABETES BY
REGION, 2010
- Figure 46: GLOBAL REVENUES FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS, 2009-2016
- Figure 47: GLOBAL MARKET SHARES OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY
SYSTEMS BY REGION, 2010
- Figure 48: GLOBAL REVENUE FOR RESPIRATORY DRUG DELIVERY SYSTEMS,
2009-2016
- Figure 49: GLOBAL MARKET SHARES OF RESPIRATORY DRUG DELIVERY SYSTEMS BY
REGION, 2010
- Figure 50: GLOBAL REVENUES FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY
DISEASES AND ALLERGIES, 2009-2016
- Figure 51: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR
INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2010
- Figure 52: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY,
2009-2016
- Figure 53: GLOBAL MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY
BY REGION, 2010
- Figure 54: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES, 2009-2016
- Figure 55: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS FOR VIRAL AND
BACTERIAL DISEASES BY REGION, 2010
- Figure 56: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY, 2009-2016
- Figure 57: GLOBAL MARKET SHARES OF DRUG DELIVERY SYSTEMS HORMONE
REPLACEMENT THERAPY AND GYNECOLOGY, 2010
- Figure 58: GLOBAL REVENUE FOR DRUG DELIVERY SYSTEMS FOR OTHER DISEASES,
2009-2016
- Figure 59: GLOBAL MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR OTHER
DISEASES BY REGION, 2010
- Figure 60: GLOBAL REVENUE FOR DRUG DELIVERY TECHNOLOGIES, 2009-2016
- Figure 61: GLOBAL MARKET SHARES OF DRUG DELIVERY TECHNOLOGIES BY REGION,
2010
- Figure 62: SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2010
- Figure 63: NUMBER OF PATENTS BY YEAR, 2007 - 2011
- Figure 64: SIGNIFICANT OF PATENTS BY YEAR, 2007 - 2011
- Figure 65: TOTAL PATENTS BY TYPE, 2007 - 2011
- Figure 66: PATENTS BY ASSIGNEE FOR DRUG DELIVERY SYSTEMS, 2007 - 2011
預計2016年時全球先進藥物遞送系統市場的收益規模將達到1,756億美元
2011年11月07日
Global Information, Inc.已開始銷售BCC Research所發行的報告書「Advanced Drug Delivery Systems: Technologies and Global Markets (先進藥物傳輸系統（DDS）：技術以及全球市場)」
2011年全球先進藥物遞送系統系統市場約為1,379億美元規模，預測之後以複合年成長率(CAGR)5％擴大，2016年之前將達到1,756億美元。
先進藥物遞送系統市場能分成美國、歐洲及其他3個地區。
2011年美國地區是816億美元規模，預計之後CAGR 以4.7％成長，2016年時達到1,026億美元。
2011年歐洲地區是375億美元規模，預計之後CAGR以 5.6％成長，2016年時達到491億美元。
2011年其他地區是約188億美元規模，預計之後CAGR 以4.8％成長，2016年時達到238億美元。
藥物遞送產業從醫藥產業的影子中浮現，現在已成為醫藥市場成長的主要原因。
預料藥物遞送技術將大幅牽引全球的醫藥及生物醫藥產業。
醫藥及生物醫藥企業已體認藥物遞送技術的策略優位性。作為學名藥侵蝕市場的對策，適用對以往藥物有相對優位性的藥物遞送。
藥物遞送市場是醫療產業已確立的重要部門。
此市場因繼續努力研究而迅速進化。許多藥物遞送系統被開發，已經改善市場以往藥劑之藥理學的許多特性。
不僅對醫藥•生物醫藥產業，對醫院、醫療和研究機關來說，該報告書亦是非常有趣的報告書。
|
